Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624839 · ClinicalTrials.gov registry record · Phase 2
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
A Phase 2 study of HIV and Human Papilloma Virus, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06624839 is a Phase 2 study of HIV and Human Papilloma Virus that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 120 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06624839, a Phase 2 study of HIV and Human Papilloma Virus, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).
Conditions Studied
Interventions
- BIOLOGICAL Human papillomavirus (HPV) vaccine, 9-valent
Study Locations (2)
District of Columbia
- RIIS Clinic at HIPS - Washington D.C.
Maryland
- RIIS Clinic at Baltimore Safe Haven - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-15 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06624839
The ClinicalTrials.gov registry entry for NCT06624839 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (73% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Human papillomavirus (HPV) vaccine, 9-valent is the first listed.
NCT06624839 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06624839 about?
NCT06624839 is a clinical study titled "Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV". This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative contro...
What is the current status of trial NCT06624839?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-03-15. Estimated completion is 2028-01.
What conditions does trial NCT06624839 study?
This clinical trial studies the following conditions: HIV, Human Papilloma Virus, Anal Dysplasia.
What interventions are being tested in trial NCT06624839?
The interventions under investigation include: Human papillomavirus (HPV) vaccine, 9-valent (BIOLOGICAL).
Who is sponsoring clinical trial NCT06624839?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624839 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.